Shares of Dynavax Technologies (NASDAQ: DVAX) were vaulting 7.2% higher as of 11:44 a.m. EST on Thursday. The big jump came after the biotech announced results from an ongoing clinical study evaluating hepatitis B vaccine Heplisav-B in patients undergoing hemodialysis.
As you might have guessed, Dynavax had good news from the clinical trial. The company reported a seroprotection rate (a measure of the production of antibodies that can protect against infection) of 89.3% for a four-dose regimen of Heplisav-B after 20 weeks. Dynavax also stated that interim safety data showed that its vaccine was well tolerated, with no safety issues observed in the study.
Image source: Getty Images.
For further details see:
Why Dynavax Stock Is Vaulting Higher Today